IOL Chemicals and Pharmaceuticals Limited (IOLCP.BO)
INR 61.65
(-5.81%)
INR 61.65
(-5.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.6 Billion INR | -6.21% |
| 2022 | 2.51 Billion INR | -13.85% |
| 2021 | 2.76 Billion INR | -53.32% |
| 2020 | 6.16 Billion INR | 4.5% |
| 2019 | 5.89 Billion INR | 40.87% |
| 2018 | 4.2 Billion INR | 243.03% |
| 2017 | 1.25 Billion INR | 23.32% |
| 2016 | 1.03 Billion INR | 167.66% |
| 2015 | 526.02 Million INR | 764.3% |
| 2014 | -55.03 Million INR | -105.96% |
| 2013 | 970.56 Million INR | 4.1% |
| 2012 | 890.59 Million INR | 29.58% |
| 2011 | 709.32 Million INR | 118.07% |
| 2010 | -3.8 Billion INR | -1062.16% |
| 2009 | 395.32 Million INR | 9.75% |
| 2008 | 360.18 Million INR | -2.0% |
| 2007 | 367.53 Million INR | 95.14% |
| 2006 | 188.35 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 511.1 Million INR | 2.54% |
| 2023 FY | - INR | -6.21% |
| 2023 Q4 | 495.2 Million INR | -6.09% |
| 2023 Q3 | 527.3 Million INR | -26.06% |
| 2023 Q2 | 713.1 Million INR | -10.39% |
| 2023 Q1 | 795.8 Million INR | -19.29% |
| 2022 Q4 | 986 Million INR | 99.84% |
| 2022 Q2 | 369.7 Million INR | -39.34% |
| 2022 Q1 | 609.5 Million INR | 28.94% |
| 2022 FY | - INR | -13.85% |
| 2022 Q3 | 493.4 Million INR | 33.46% |
| 2021 Q1 | 1.15 Billion INR | 2.92% |
| 2021 Q3 | 680.9 Million INR | 25.37% |
| 2021 FY | - INR | -53.32% |
| 2021 Q2 | 543.1 Million INR | -53.13% |
| 2021 Q4 | 472.7 Million INR | -30.58% |
| 2020 Q1 | 1.57 Billion INR | 15.03% |
| 2020 Q4 | 1.12 Billion INR | -31.79% |
| 2020 Q2 | 1.75 Billion INR | 11.31% |
| 2020 FY | - INR | 4.5% |
| 2020 Q3 | 1.65 Billion INR | -6.1% |
| 2019 Q3 | 1.63 Billion INR | 19.92% |
| 2019 Q1 | 1.47 Billion INR | -4.31% |
| 2019 FY | - INR | 40.87% |
| 2019 Q4 | 1.37 Billion INR | -16.01% |
| 2019 Q2 | 1.36 Billion INR | -7.86% |
| 2018 Q3 | 1.36 Billion INR | 68.57% |
| 2018 Q2 | 808.9 Million INR | 86.25% |
| 2018 Q1 | 434.3 Million INR | 22.55% |
| 2018 FY | - INR | 243.03% |
| 2018 Q4 | 1.54 Billion INR | 13.37% |
| 2017 Q3 | 327.8 Million INR | 9.19% |
| 2017 FY | - INR | 23.32% |
| 2017 Q4 | 354.4 Million INR | 8.11% |
| 2017 Q1 | 276.2 Million INR | 4.27% |
| 2017 Q2 | 300.2 Million INR | 8.69% |
| 2016 FY | - INR | 167.66% |
| 2016 Q4 | 264.9 Million INR | 2.95% |
| 2016 Q3 | 257.3 Million INR | 0.9% |
| 2016 Q2 | 255 Million INR | -0.89% |
| 2016 Q1 | 257.3 Million INR | 181.31% |
| 2015 Q2 | 82.4 Million INR | 283.4% |
| 2015 Q4 | 91.46 Million INR | -46.51% |
| 2015 FY | - INR | 764.3% |
| 2015 Q1 | 21.49 Million INR | 115.4% |
| 2015 Q3 | 171 Million INR | 107.52% |
| 2014 FY | - INR | -105.96% |
| 2014 Q4 | -139.54 Million INR | -36.14% |
| 2014 Q3 | -102.5 Million INR | -249.0% |
| 2014 Q2 | 68.79 Million INR | -72.34% |
| 2014 Q1 | 248.7 Million INR | 10.23% |
| 2013 Q4 | 225.61 Million INR | -4.52% |
| 2013 FY | - INR | 4.1% |
| 2013 Q1 | 244.54 Million INR | 25.56% |
| 2013 Q2 | 251.14 Million INR | 2.7% |
| 2013 Q3 | 236.28 Million INR | -5.92% |
| 2012 Q2 | 223.98 Million INR | -3.68% |
| 2012 Q3 | 239.31 Million INR | 6.85% |
| 2012 Q4 | 194.76 Million INR | -18.62% |
| 2012 FY | - INR | 29.58% |
| 2012 Q1 | 232.53 Million INR | 0.0% |
| 2011 FY | - INR | 118.07% |
| 2010 FY | - INR | -1062.16% |
| 2009 FY | - INR | 9.75% |
| 2008 FY | - INR | -2.0% |
| 2007 FY | - INR | 95.14% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bal Pharma Limited | 345.59 Million INR | -654.242% |
| Achyut Healthcare Limited | 524 Thousand INR | -497342.748% |
| Alkem Laboratories Limited | 24.19 Billion INR | 89.227% |
| Divi's Laboratories Limited | 25.43 Billion INR | 89.75% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 77.022% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 62.019% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 3250.846% |
| Mankind Pharma Limited | 28.09 Billion INR | 90.722% |
| Medicamen Biotech Limited | 245.66 Million INR | -961.06% |
| Medico Remedies Limited | 150.37 Million INR | -1633.365% |
| Megasoft Limited | 284.73 Million INR | -815.461% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 13.528% |
| Piramal Pharma Limited | 13.05 Billion INR | 80.034% |
| Sequent Scientific Limited | 549.8 Million INR | -374.1% |
| Sigachi Industries Limited | 883.39 Million INR | -195.065% |
| Ajanta Pharma Limited | 12.56 Billion INR | 79.256% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.116% |
| Brooks Laboratories Limited | 41.72 Million INR | -6146.645% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 33.325% |
| Themis Medicare Limited | 562.6 Million INR | -363.307% |
| Unichem Laboratories Limited | 742.35 Million INR | -251.125% |
| Hester Biosciences Limited | 539.47 Million INR | -383.178% |
| Venus Remedies Limited | 711.8 Million INR | -266.198% |
| Indoco Remedies Limited | 2.64 Billion INR | 1.528% |
| Ind-Swift Limited | 1.06 Billion INR | -144.736% |
| Aarti Drugs Limited | 3.24 Billion INR | 19.763% |
| Alpa Laboratories Limited | 86.12 Million INR | -2926.461% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -10.599% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 97.047% |
| Granules India Limited | 8.6 Billion INR | 69.704% |
| Gufic Biosciences Limited | 1.48 Billion INR | -76.064% |
| Hikal Limited | 2.69 Billion INR | 3.181% |
| RPG Life Sciences Limited | 1.28 Billion INR | -103.402% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 44.27% |
| Windlas Biotech Limited | 781.72 Million INR | -233.444% |
| ZIM Laboratories Limited | 462.09 Million INR | -464.081% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 62.012% |
| Jubilant Pharmova Limited | 8 Billion INR | 67.442% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 95.781% |
| Bajaj HealthCare Limited | 444.51 Million INR | -486.391% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -19855.596% |
| Ipca Laboratories Limited | 13.29 Billion INR | 80.401% |
| Lasa Supergenerics Limited | -65.08 Million INR | 4105.224% |
| Laurus Labs Limited | 8 Billion INR | 67.442% |
| NATCO Pharma Limited | 18.79 Billion INR | 86.131% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -66.685% |
| Shilpa Medicare Limited | 2.58 Billion INR | -0.719% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 192.37% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 92.555% |
| Wanbury Limited | 985.49 Million INR | -164.498% |
| Wockhardt Limited | 1.08 Billion INR | -141.352% |
| Strides Pharma Science Limited | 3.76 Billion INR | 30.762% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -76.237% |
| Suven Life Sciences Limited | -992.78 Million INR | 362.556% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -281.898% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 72.895% |
| Eris Lifesciences Limited | 6.98 Billion INR | 62.691% |
| Lupin Limited | 36.96 Billion INR | 92.949% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 169.858% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -505.797% |
| Valiant Laboratories Limited | 12.73 Million INR | -20361.575% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 95.364% |
| FDC Limited | 4.4 Billion INR | 40.782% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 72.077% |
| Novartis India Limited | 1.26 Billion INR | -105.357% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -705.849% |
| Neuland Laboratories Limited | 4.74 Billion INR | 45.103% |
| Morepen Laboratories Limited | 1.72 Billion INR | -51.024% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -806.88% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -1389.945% |